Moderna Inc. shares tumbled after the company said it expected revenue to fall sharply next year to well below what analysts were expecting, raising concerns about the company's plan to pay for its ambitious pipeline. The vaccine maker sees revenue falling to about $4 billion next year, with sales growth resuming in 2025 as new vaccines hit the market. Analysts were expecting about $6 billion in sales next year. Moderna also reported a larger-than-expected loss in the third quarter after registering a $3.1 billion charge to write down excess Covid shots and reduce its manufacturing footprint as the vaccine maker prepares for a post-pandemic era.